Suppr超能文献

过表达 microRNA-34a 通过抑制 DLL1 克服结肠癌侧群细胞中 ABCG2 介导的 5-FU 耐药性。

Overexpressing microRNA-34a overcomes ABCG2-mediated drug resistance to 5-FU in side population cells from colon cancer via suppressing DLL1.

机构信息

Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

Medical College of Nanchang University, Nanchang, Jiangxi 330000, China.

出版信息

J Biochem. 2020 Jun 1;167(6):557-564. doi: 10.1093/jb/mvaa012.

Abstract

Colon cancer side population (SP) cells are a small subset of cancer cells that have cancer stemness capacity and enhanced drug resistance. ABCG2 is a multidrug resistance-related protein in SP cells and has been demonstrated to be regulated by Notch signalling pathway. Recently, microRNAs are reported to play a critical role in SP cell fate. However, their role in ABCG2-mediated drug resistance in colon cancer SP cells remains unclear. In the current study, the different expressions of miR-552, miR-611, miR-34a and miR-5000-3p were compared within SP and non-SP cells, which were separated from human colon cancer cell lines (SW480 and LoVo). We found that miR-34a was significantly down-regulated in SP cells and that overexpressing miR-34a overcame drug resistance to 5-fluorouracil (5-FU). The luciferase reporter assay indicated that miR-34a negatively regulated DLL1, a ligand of Notch signalling pathway, via binding with 3'-untranslated region of its messenger RNA. In addition, overexpressing miR-34a overcame ABCG2-mediated resistance to 5-FU via DLL1/Notch pathway in vitro, and suppressed tumour growth under 5-FU treatment in vivo. In conclusion, our findings suggest that miR-34a acts as a tumour suppressor via enhancing chemosensitivity to 5-FU in SP cells, which provides a novel therapeutic target in chemotherapy-resistant colon cancer.

摘要

结肠癌侧群(SP)细胞是一小部分具有癌症干性能力和增强耐药性的癌细胞。ABCG2 是 SP 细胞中一种多药耐药相关蛋白,已被证明受 Notch 信号通路调节。最近,microRNAs 被报道在 SP 细胞命运中发挥关键作用。然而,它们在结肠癌 SP 细胞中 ABCG2 介导的药物耐药中的作用尚不清楚。在本研究中,比较了从人结肠癌细胞系(SW480 和 LoVo)中分离的 SP 和非 SP 细胞中 miR-552、miR-611、miR-34a 和 miR-5000-3p 的不同表达。我们发现 miR-34a 在 SP 细胞中显著下调,过表达 miR-34a 可克服 5-氟尿嘧啶(5-FU)的耐药性。荧光素酶报告基因检测表明,miR-34a 通过结合其信使 RNA 的 3'-非翻译区,负调控 Notch 信号通路的配体 DLL1。此外,过表达 miR-34a 通过 DLL1/Notch 通路在体外克服 ABCG2 介导的 5-FU 耐药性,并在体内 5-FU 治疗下抑制肿瘤生长。总之,我们的研究结果表明,miR-34a 通过增强 SP 细胞对 5-FU 的化疗敏感性发挥肿瘤抑制作用,为化疗耐药性结肠癌提供了一个新的治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验